Evaluating only Goldfinch Bio’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Product failure.
Key Events Timeline
FOUNDING
Goldfinch Bio founded by Third Rock Ventures in Cambridge, MA to target TRPC5 ion channel in kidney disease.
FUNDING
$100M Series B raised; GFB-887 enters Phase 2 for focal segmental glomerulosclerosis, a rare progressive kidney disease.
GFB-887 Phase 2 fails; Goldfinch Bio shuts down entirely within weeks, 75 employees terminated, assets dissolved.
Full Analysis
Free · no account needed
Documented cause
Goldfinch Bio, a kidney disease precision medicine startup backed by $165M from Third Rock Ventures and others, shut down in May 2023 after its lead drug GFB-887 for FSGS failed Phase 2 with no statistically significant reduction in proteinuria at 12 weeks in a 100-patient trial. CEO Aimee Zarriello announced the closure immediately after data readout, citing no alternative clinical programs to fund. The entire 75-person workforce was terminated, and the company was dissolved within 60 days of the trial failure.
Lesson
“Single-asset kidney disease biotechs must validate proteinuria biomarker thresholds in Phase 1b before pivotal expansion.”